Read by QxMD icon Read

Colorectal tumour

Alessandro Mantovani, Marco Dauriz, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Enzo Bonora, Giovanni Targher
BACKGROUND: It is currently uncertain whether non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of colorectal tumours. We performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between NAFLD and risk of colorectal adenomas and cancer. METHODS: We searched PubMed, Scopus and Web of Science from January 2000 to November 2017 using pre-defined keywords to identify observational studies of asymptomatic adults undergoing screening colonoscopy, in which NAFLD was diagnosed by imaging or histology...
June 20, 2018: Metabolism: Clinical and Experimental
Ciro Franzese, Tiziana Comito, Elena Clerici, Lucia Di Brina, Stefano Tomatis, Pierina Navarria, Giacomo Reggiori, Luca Viganò, Dario Poretti, Vittorio Pedicini, Guido Torzilli, Luigi Solbiati, Marta Scorsetti
PURPOSE: The study aim was to compare the disease control in two groups of patients affected by liver metastases from CRC treated with microwave ablation (MWA) or stereotactic body radiation therapy (SBRT). METHODS: We extracted data of patients treated between 2009 and 2016. Inclusion criteria were: (1) maximum diameter of the liver lesions less than 4 cm; (2) no more than three liver lesions; (3) no evidence of progressive or untreated gross disease outside the liver; (4) adequate liver function; (5) no concurrent chemotherapy; (6) minimum age of 18...
June 22, 2018: Journal of Cancer Research and Clinical Oncology
Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, Robert P Jones, Lorenzo Ressel, Carrie A Duckworth, D Mark Pritchard, Zhi-Xiu Lin, Fretwell L Vicky, Elizabeth M Tweedle, Eithne Costello, Christopher E Goldring, Ian M Copple, B Kevin Park, Daniel H Palmer, Neil R Kitteringham
Nrf2 is a transcription factor that regulates cellular stress response and irinotecan-metabolising pathways. Its aberrant activity has been reported in a number of cancers, although relatively few studies have explored a role for Nrf2 in colorectal cancer (CRC). This study assessed the expression of Nrf2 in patient CRC tissues and explored the effect of Nrf2 modulation alone, or in combination with irinotecan, in human (HCT116) and murine (CT26) cell lines in vitro and in an orthotopic syngeneic mouse model utilising bioluminescent imaging...
June 5, 2018: Oncotarget
R F Kokelaar, H Jones, J Beynon, M E Evans, D A Harris
PURPOSE: The pathological and prognostic importance of CpG island methylator phenotype (CIMP) in rectal cancer, as a sub-population of colorectal cancer, is unknown. A meta-analysis was preformed to estimate the prognostic significance of CIMP in rectal cancer. METHODS: A systematic search was performed of PubMed, Embase, MEDLINE, PubMed Central, and Cochrane electronic databases for articles pertaining to CIMP and rectal cancer. Articles were analysed and data extracted according to PRISMA standards...
June 20, 2018: International Journal of Colorectal Disease
John M Creasy, Abhishek Midya, Jayasree Chakraborty, Lauryn B Adams, Camilla Gomes, Mithat Gonen, Kenneth P Seastedt, Elizabeth J Sutton, Andrea Cercek, Nancy E Kemeny, Jinru Shia, Vinod P Balachandran, T Peter Kingham, Peter J Allen, Ronald P DeMatteo, William R Jarnagin, Michael I D'Angelica, Richard K G Do, Amber L Simpson
OBJECTIVES: This study investigates whether quantitative image analysis of pretreatment CT scans can predict volumetric response to chemotherapy for patients with colorectal liver metastases (CRLM). METHODS: Patients treated with chemotherapy for CRLM (hepatic artery infusion (HAI) combined with systemic or systemic alone) were included in the study. Patients were imaged at baseline and approximately 8 weeks after treatment. Response was measured as the percentage change in tumour volume from baseline...
June 19, 2018: European Radiology
Gabrielle H van Ramshorst, Sarah 'o Shannassy, Wendy E Brown, James G Kench, Michael J Solomon
AIM: Pelvic exenteration surgery remains the only curative option for recurrent rectal cancer. Microscopically involved surgical margins (R1) are associated with a higher risk of local recurrence and decreased survival. Our study aimed to develop a post hoc multidisciplinary case conference review and investigate its potential for identifying areas for improvement. METHOD: Patients who underwent pelvic exenteration surgery for recurrent rectal cancer with R1 resections at a tertiary referral center between April 2014- January 2016 were retrospectively reviewed from a prospectively maintained database...
June 19, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Marko Klobučar, Petra Grbčić, Sandra Kraljević Pavelić, Nives Jonjić, Sarah Visentin, Mirela Sedić
Acid ceramidase (ASAH1) has been implicated in the progression and chemoresistance in different cancers. Its role in colon cancer biology and response to standard chemotherapy has been poorly addressed so far. Here, we have investigated ASAH1 expression at the protein level in human colon cancer cell lines and tissues from colon cancer patients, and have examined in vitro the possible link between ASAH1 expression and functional activity of p53 protein whose inactivation is associated with the progression from adenoma to malignant tumour in colon cancer...
June 16, 2018: Biochemical and Biophysical Research Communications
Nina C A Vermeer, Renu R Bahadoer, Esther Bastiaannet, Fabian A Holman, Elma Meershoek-Klein Kranenbarg, Gerrit-Jan Liefers, Cornelis J H van de Velde, Koen C M J Peeters
AIM: In 2014, a national colorectal cancer (CRC) screening program was launched in the Netherlands. It is difficult to assess for the individual CRC patient whether the oncological benefits of surgery will outweigh the morbidity of the procedure, especially in early lesions. This study compares patient and tumour characteristics between screen-detected and non-screen-detected patients. Secondly, we present an overview of treatment options and clinical dilemmas when treating patients with early stage colorectal disease...
June 19, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Susanne Merkel, Vera S Schellerer, Axel Wein, Sabine Semrau, Carol Geppert, Jonas Göhl, Werner Hohenberger, Klaus Weber, Robert Grützmann
PURPOSE: The aim of our study was to compare the characteristics and prognosis between right- and left-sided metastatic colorectal carcinomas. METHODS: Data from 937 patients with stage IV colorectal carcinomas (synchronous distant metastasis) who had a resection of the primary tumour between 1985 and 2014 were analysed. Carcinomas in the caecum to transverse colon were defined as right-sided (n = 250; 26.7%). They were compared to tumours located from the splenic flexure to the rectum categorised as left-sided (n = 687; 73...
June 18, 2018: International Journal of Colorectal Disease
Mohammed Y Khanji, Muhamad Abd Razak, Timothy J Bowker, Steffen E Petersen
No abstract text is available yet for this article.
April 18, 2018: European Heart Journal
S Qiu, G Pellino, O J Warren, S Mills, R Goldin, C Kontovounisios, P P Tekkis
Mixed adenoneuroendocrine carcinoma (MANEC) are rare cancers of the gastrointestinal (GI) and pancreatobiliary tract. They are characterized by the presence of a combination of epithelial and neuroendocrine elements, where each component represents at least 30% of the tumour. Review of literature and consolidation of clinicopathological data. Sixty-one cases of colorectal MANEC have been reported in literature and one seen in this centre. The median age of the patients affected was 61.9 ± 12.4 years (20-94 years)...
June 17, 2018: Acta Chirurgica Belgica
Gemma Bruera, Francesco Pepe, Umberto Malapelle, Pasquale Pisapia, Antonella Dal Mas, Daniela Di Giacomo, Giuseppe Calvisi, Giancarlo Troncone, Enrico Ricevuto
Background: First line triplet chemotherapy/BEV significantly improved clinical outcome of MCRC. KRAS/NRAS/BRAF mutations were evaluated by next generation sequencing (NGS) in MCRC patients treated with first line FIr-B/FOx. Methods: KRAS exons 2-4 ( KRAS 2-4 ), NRAS 2-4 , BRAF 15 were evaluated in 67 tumours by ION Torrent platform. Mutation detection criteria: >500×sequence coverage (cov); >1% mutant allelic fraction (AF). Clinical outcomes were compared by log-rank...
May 29, 2018: Oncotarget
Qing Liu, Julie A Thoms, Andrea C Nunez, Yizhou Huang, Kathy Knezevic, Deborah Packham, Rebecca C Poulos, Rachel Williams, Dominik Beck, Nicholas J Hawkins, Robyn L Ward, Jason W H Wong, Luke B Hesson, Mathew A Sloane, John Pimanda
PURPOSE: MLH1 is a major tumour suppressor gene involved in the pathogenesis of Lynch syndrome and various sporadic cancers. Despite their potential pathogenic importance, genomic regions capable of regulating MLH1 expression over long distances have yet to be identified. EXPERIMENTAL DESIGN: Here we use chromosome conformation capture (3C) to screen a 650-kb region flanking the MLH1 locus to identify interactions between the MLH1 promoter and distal regions in MLH1 expressing and non-expressing cells...
June 13, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Aires Martins, Alvaro Gonçalves, Teresa Almeida, Alberto Midões
Carcinoembryonic antigen (CEA) is still the most widely used tumour marker for gastrointestinal cancer. CEA was originally thought to be a specific marker for colorectal cancer, but it turned out to be a non-specific marker for further studies. CEA levels can be elevated in breast, lung and liver cancers, among others, including medullary thyroid cancer. The authors report a case of a 73-year-old woman who had a right hemicolectomy for an ascending colon adenocarcinoma and showed a persistent elevation in the CEA marker during follow-up...
June 11, 2018: BMJ Case Reports
Morgane Bouquot, Ben Creavin, Nicolas Goasguen, Najim Chafai, Emmanuel Tiret, Thierry André, Jean-Francois Flejou, Yann Parc, Jérémie H Lefevre, Magali Svrcek
The presence of tumor deposits (TD) in colorectal cancer (CRC) is associated with poor prognosis. The 7th edition of TNM subclassified a new nodal stage, N1c, characterized by the presence of TD without any concurrent positive lymph node (LN). It is not clear if the N1c category is equal or not to LN metastasis. We aimed to examine the prevalence, characteristics and prognostic significance of this new subcategory METHODS: Consecutive patients who underwent surgery for CRC in two centers (2011-2014) were analyzed...
June 12, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
A M Lucchese, A N Kalil, A Ruiz, V Karam, O Ciacio, G Pittau, D Castaing, D Cherqui, A Sa Cunha, E Vibert, R Adam
BACKGROUND: Indications for surgical resection of non-colorectal, non-neuroendocrine (NCNNE) liver metastases are unclear. This study analysed the influence of response to neoadjuvant chemotherapy and the presence of extrahepatic disease (EHD) on outcomes. METHODS: Patients who underwent hepatic resection for NCNNE liver metastases and who received neoadjuvant chemotherapy at a single centre between 1982 and 2016 were analysed retrospectively. Patients were classified as having no EHD, controlled EHD or non-controlled EHD...
June 12, 2018: British Journal of Surgery
Naomi Yoshuantari, Didik Setyo Heriyanto, Susanna Hilda Hutajulu, Johan Kurnianda, Ahmad Ghozali
Background: Colorectal cancer (CRC) is both a global and national burden, being the third most common malignancy in men and the second in women, worldwide. The prognosis of CRC is affected by various factors like the histological grade, angiolymphatic invasion, and distant metastases. Metastasis is an intricate process; one of the possible mechanisms is through the interaction of the chemokines CXCL12 and CXCR4. This study aims to reveal the expression patterns of CXCL12 and CXCR4 in CRC...
2018: Gastroenterology Research and Practice
Edith Lahner, Marina Capasso, Marilia Carabotti, Bruno Annibale
BACKGROUND: Pernicious anaemia (PA) is associated with increased gastric cancer risk, but the evidence is conflicting regarding the associated risk of other cancers. AIM: To systematically determine the incidence rates of gastro-intestinal cancers other than gastric cancers (GI-other-than-GC) and non-gastrointestinal cancers (non-GIC) in PA adults, globally and per tumour site, and the risk associated with PA for GI-other than GC and non-GIC. METHODS: Studies of PA patients reporting the incidence of GI-other-than-GCs and non-GICs were identified with MEDLINE (PubMed)-EMBASE (from first date available to April 2017)...
May 24, 2018: Digestive and Liver Disease
Matthias F Froelich, Volker Heinemann, Wieland H Sommer, Julian W Holch, Franziska Schoeppe, Nina Hesse, Alena B Baumann, Wolfgang G Kunz, Maximilian F Reiser, Jens Ricke, Melvin D'Anastasi, Sebastian Stintzing, Dominik P Modest, Philipp M Kazmierczak, Felix O Hofmann
OBJECTIVES: To assess the prognostic value of pre-therapeutic computed tomography (CT) attenuation of liver metastases for overall survival (OS) in metastatic colorectal cancer (mCRC). METHODS: In the open-label, randomised, prospective phase-III FIRE-3 trial, patients with histologically confirmed mCRC received fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) with either cetuximab or bevacizumab. Participating patients gave written informed consent prior to study entry...
June 7, 2018: European Radiology
Ying Zhao, Ling Wang, Xueying Zhai, Tao Cui, Guijiang Wang, Qijun Pang
Biochanin A has been reported to be associated to tumour cell proliferation, apoptosis and drug resistance in hepatocellular carcinoma, prostate cancer, and colorectal cancer, etc, while the relation of biochanin A on osteosarcoma is not clear. Hence, in this study, we examined the effects of biochanin A treatment on osteosarcoma cell lines MG63 and U2OS on proliferation, apoptosis, invasion and migration. We then investigated the involved molecular mechanism and found a time- and dose-dependent inhibition of cell viability in MG63 and U2OS cells with biochanin A treatment...
June 1, 2018: Die Pharmazie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"